context stringlengths 21 33.9k | category stringclasses 2 values | entity stringlengths 1 12 | entity_type stringclasses 5 values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The Company had several defined benefit pension plans in locations outside of the United States. The total projected benefit obligation, assets and unfunded liability for these plans as of year-end 2023 were $ 9.7 million, $ 8.0 million and $ 1.7 million, respectively, all of which were included as held for sale (see Acquisitions and Dispositions footnote). Total pension expense for these plans was $ 0.2 million in 2023 and $ 0.4 million in 2022. These plans are no longer effective in 2024. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company had several defined benefit pension plans in locations outside of the United States. The total projected benefit obligation, assets and unfunded liability for these plans as of year-end 2023 were $ 9.7 million, $ 8.0 million and $ 1.7 million, respectively, all of which were included as held for sale (see Acquisitions and Dispositions footnote). Total pension expense for these plans was $ 0.2 million in 2023 and $ 0.4 million in 2022. These plans are no longer effective in 2024. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The Company had several defined benefit pension plans in locations outside of the United States. The total projected benefit obligation, assets and unfunded liability for these plans as of year-end 2023 were $ 9.7 million, $ 8.0 million and $ 1.7 million, respectively, all of which were included as held for sale (see Acquisitions and Dispositions footnote). Total pension expense for these plans was $ 0.2 million in 2023 and $ 0.4 million in 2022. These plans are no longer effective in 2024. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company had several defined benefit pension plans in locations outside of the United States. The total projected benefit obligation, assets and unfunded liability for these plans as of year-end 2023 were $ 9.7 million, $ 8.0 million and $ 1.7 million, respectively, all of which were included as held for sale (see Acquisitions and Dispositions footnote). Total pension expense for these plans was $ 0.2 million in 2023 and $ 0.4 million in 2022. These plans are no longer effective in 2024. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The authorized capital stock of the Company is 100,000,000 shares of Class A common stock and 10,000,000 shares of Class B common stock. Class A shares have no voting rights and are not convertible. Class B shares have voting rights and are convertible by the holder into Class A shares on a share-for-share basis at any time. Both classes of stock have identical rights in the event of liquidation. The voting rights of Class B shares are perpetual and Class B shares are not subject to transfer restrictions or mandatory conversion obligations under the Company's certificate of incorporation or bylaws. | text | 100000000 | sharesItemType | text: <entity> 100000000 </entity> <entity type> sharesItemType </entity type> <context> The authorized capital stock of the Company is 100,000,000 shares of Class A common stock and 10,000,000 shares of Class B common stock. Class A shares have no voting rights and are not convertible. Class B shares have voting rights and are convertible by the holder into Class A shares on a share-for-share basis at any time. Both classes of stock have identical rights in the event of liquidation. The voting rights of Class B shares are perpetual and Class B shares are not subject to transfer restrictions or mandatory conversion obligations under the Company's certificate of incorporation or bylaws. </context> | us-gaap:CommonStockSharesAuthorized |
The authorized capital stock of the Company is 100,000,000 shares of Class A common stock and 10,000,000 shares of Class B common stock. Class A shares have no voting rights and are not convertible. Class B shares have voting rights and are convertible by the holder into Class A shares on a share-for-share basis at any time. Both classes of stock have identical rights in the event of liquidation. The voting rights of Class B shares are perpetual and Class B shares are not subject to transfer restrictions or mandatory conversion obligations under the Company's certificate of incorporation or bylaws. | text | 10000000 | sharesItemType | text: <entity> 10000000 </entity> <entity type> sharesItemType </entity type> <context> The authorized capital stock of the Company is 100,000,000 shares of Class A common stock and 10,000,000 shares of Class B common stock. Class A shares have no voting rights and are not convertible. Class B shares have voting rights and are convertible by the holder into Class A shares on a share-for-share basis at any time. Both classes of stock have identical rights in the event of liquidation. The voting rights of Class B shares are perpetual and Class B shares are not subject to transfer restrictions or mandatory conversion obligations under the Company's certificate of incorporation or bylaws. </context> | us-gaap:CommonStockSharesAuthorized |
In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. | text | 742163 | sharesItemType | text: <entity> 742163 </entity> <entity type> sharesItemType </entity type> <context> In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. </context> | us-gaap:TreasuryStockSharesAcquired |
In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. </context> | us-gaap:PaymentsForRepurchaseOfCommonStock |
In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. | text | 13.49 | perShareItemType | text: <entity> 13.49 </entity> <entity type> perShareItemType </entity type> <context> In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. | text | 40.0 | monetaryItemType | text: <entity> 40.0 </entity> <entity type> monetaryItemType </entity type> <context> In November 2024, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program that expires on December 2, 2026. During December 2024, the Company repurchased 742,163 Class A shares for $ 10.0 million at an average price of $ 13.49 per share. A total of $ 40.0 million remains available under the share repurchase program as of year-end 2024. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 2496827 | sharesItemType | text: <entity> 2496827 </entity> <entity type> sharesItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:TreasuryStockSharesAcquired |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 42.2 | monetaryItemType | text: <entity> 42.2 </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:PaymentsForRepurchaseOfCommonStock |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 474644 | sharesItemType | text: <entity> 474644 </entity> <entity type> sharesItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:TreasuryStockSharesAcquired |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 7.8 | monetaryItemType | text: <entity> 7.8 </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:PaymentsForRepurchaseOfCommonStock |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 42.2 | monetaryItemType | text: <entity> 42.2 </entity> <entity type> monetaryItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 2971471 | sharesItemType | text: <entity> 2971471 </entity> <entity type> sharesItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:TreasuryStockSharesAcquired |
In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. | text | 16.83 | perShareItemType | text: <entity> 16.83 </entity> <entity type> perShareItemType </entity type> <context> In November 2022, the Company's board of directors authorized a $ 50.0 million Class A share repurchase program, which was completed in August 2023. During 2023 and 2022, the Company repurchased 2,496,827 Class A shares for $ 42.2 million and 474,644 Class A shares for $ 7.8 million, respectively. There were no remaining shares available under the share repurchase program as of year-end 2023 as compared to $ 42.2 million remaining shares available under the share repurchase program as of year-end 2022. A total of 2,971,471 shares were repurchased under the share repurchase program at an average price of $ 16.83 per share. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
Of the amount included in this line item $ 1.9 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to the investment in PersolKelly Pte. Ltd. (see Investment in PersolKelly Pte. Ltd. footnote for more details). In addition, $ 1.4 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to other activities and $ 1.4 million in 2022 was recorded in loss on disposal line item in the consolidated statements of earnings related to the liquidation of the cumulative translation adjustment for the sale of our Russia operations (see Acquisitions and Dispositions footnote for more details). All amounts in prior years were recorded in other income (expense), net in the consolidated statements of earnings. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> Of the amount included in this line item $ 1.9 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to the investment in PersolKelly Pte. Ltd. (see Investment in PersolKelly Pte. Ltd. footnote for more details). In addition, $ 1.4 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to other activities and $ 1.4 million in 2022 was recorded in loss on disposal line item in the consolidated statements of earnings related to the liquidation of the cumulative translation adjustment for the sale of our Russia operations (see Acquisitions and Dispositions footnote for more details). All amounts in prior years were recorded in other income (expense), net in the consolidated statements of earnings. </context> | us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent |
Of the amount included in this line item $ 1.9 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to the investment in PersolKelly Pte. Ltd. (see Investment in PersolKelly Pte. Ltd. footnote for more details). In addition, $ 1.4 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to other activities and $ 1.4 million in 2022 was recorded in loss on disposal line item in the consolidated statements of earnings related to the liquidation of the cumulative translation adjustment for the sale of our Russia operations (see Acquisitions and Dispositions footnote for more details). All amounts in prior years were recorded in other income (expense), net in the consolidated statements of earnings. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Of the amount included in this line item $ 1.9 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to the investment in PersolKelly Pte. Ltd. (see Investment in PersolKelly Pte. Ltd. footnote for more details). In addition, $ 1.4 million in 2022 was recorded in the other income (expense), net line item in the consolidated statements of earnings related to other activities and $ 1.4 million in 2022 was recorded in loss on disposal line item in the consolidated statements of earnings related to the liquidation of the cumulative translation adjustment for the sale of our Russia operations (see Acquisitions and Dispositions footnote for more details). All amounts in prior years were recorded in other income (expense), net in the consolidated statements of earnings. </context> | us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent |
Due to our net loss in 2024, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan and performance shares, of 0.4 million shares in 2024, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. Potentially dilutive shares outstanding for 2023 are primarily related to deferred common stock related to the non-employee directors deferred compensation plan and performance shares (see Stock-Based Compensation footnote for a description of performance shares). Due to our net loss in 2022, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan, of 0.2 million shares in 2022, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. | text | 0.4 | sharesItemType | text: <entity> 0.4 </entity> <entity type> sharesItemType </entity type> <context> Due to our net loss in 2024, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan and performance shares, of 0.4 million shares in 2024, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. Potentially dilutive shares outstanding for 2023 are primarily related to deferred common stock related to the non-employee directors deferred compensation plan and performance shares (see Stock-Based Compensation footnote for a description of performance shares). Due to our net loss in 2022, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan, of 0.2 million shares in 2022, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Due to our net loss in 2024, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan and performance shares, of 0.4 million shares in 2024, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. Potentially dilutive shares outstanding for 2023 are primarily related to deferred common stock related to the non-employee directors deferred compensation plan and performance shares (see Stock-Based Compensation footnote for a description of performance shares). Due to our net loss in 2022, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan, of 0.2 million shares in 2022, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. | text | 0.2 | sharesItemType | text: <entity> 0.2 </entity> <entity type> sharesItemType </entity type> <context> Due to our net loss in 2024, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan and performance shares, of 0.4 million shares in 2024, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. Potentially dilutive shares outstanding for 2023 are primarily related to deferred common stock related to the non-employee directors deferred compensation plan and performance shares (see Stock-Based Compensation footnote for a description of performance shares). Due to our net loss in 2022, potentially dilutive shares outstanding, primarily related to deferred common stock associated with the non-employee directors deferred compensation plan, of 0.2 million shares in 2022, had an anti-dilutive effect on diluted earnings per share and were excluded from the computation. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Under the Equity Incentive Plan, amended and restated February 15, 2017 and approved by the stockholders of the Company on May 10, 2017 (the “EIP”), the Company may grant to key employees restricted stock and performance awards associated with the Company’s Class A stock. The amended EIP provides that the maximum number of shares available for grants is 4.7 million. Shares available for future grants at year-end 2024 are 1.3 million. The Company issues shares out of treasury stock to satisfy stock-based awards, if available; otherwise new shares of common stock are issued from authorized shares. The Company presently has no intent to repurchase additional shares for the purpose of satisfying stock-based awards. | text | 4.7 | sharesItemType | text: <entity> 4.7 </entity> <entity type> sharesItemType </entity type> <context> Under the Equity Incentive Plan, amended and restated February 15, 2017 and approved by the stockholders of the Company on May 10, 2017 (the “EIP”), the Company may grant to key employees restricted stock and performance awards associated with the Company’s Class A stock. The amended EIP provides that the maximum number of shares available for grants is 4.7 million. Shares available for future grants at year-end 2024 are 1.3 million. The Company issues shares out of treasury stock to satisfy stock-based awards, if available; otherwise new shares of common stock are issued from authorized shares. The Company presently has no intent to repurchase additional shares for the purpose of satisfying stock-based awards. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized |
Under the Equity Incentive Plan, amended and restated February 15, 2017 and approved by the stockholders of the Company on May 10, 2017 (the “EIP”), the Company may grant to key employees restricted stock and performance awards associated with the Company’s Class A stock. The amended EIP provides that the maximum number of shares available for grants is 4.7 million. Shares available for future grants at year-end 2024 are 1.3 million. The Company issues shares out of treasury stock to satisfy stock-based awards, if available; otherwise new shares of common stock are issued from authorized shares. The Company presently has no intent to repurchase additional shares for the purpose of satisfying stock-based awards. | text | 1.3 | sharesItemType | text: <entity> 1.3 </entity> <entity type> sharesItemType </entity type> <context> Under the Equity Incentive Plan, amended and restated February 15, 2017 and approved by the stockholders of the Company on May 10, 2017 (the “EIP”), the Company may grant to key employees restricted stock and performance awards associated with the Company’s Class A stock. The amended EIP provides that the maximum number of shares available for grants is 4.7 million. Shares available for future grants at year-end 2024 are 1.3 million. The Company issues shares out of treasury stock to satisfy stock-based awards, if available; otherwise new shares of common stock are issued from authorized shares. The Company presently has no intent to repurchase additional shares for the purpose of satisfying stock-based awards. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 11.8 | monetaryItemType | text: <entity> 11.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 9.7 | monetaryItemType | text: <entity> 9.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 7.8 | monetaryItemType | text: <entity> 7.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 2.6 | monetaryItemType | text: <entity> 2.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. | text | 1.1 | monetaryItemType | text: <entity> 1.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognized stock-based compensation cost of $ 11.8 million in 2024, $ 9.7 million in 2023 and $ 7.8 million in 2022, as well as related tax benefits of $ 2.6 million in 2024, $ 1.7 million in 2023 and $ 1.1 million in 2022. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 14.5 | monetaryItemType | text: <entity> 14.5 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 20.70 | perShareItemType | text: <entity> 20.70 </entity> <entity type> perShareItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 17.33 | perShareItemType | text: <entity> 17.33 </entity> <entity type> perShareItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 20.16 | perShareItemType | text: <entity> 20.16 </entity> <entity type> perShareItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 6.5 | monetaryItemType | text: <entity> 6.5 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to unvested restricted stock totaled $ 14.5 million. The weighted average period over which this cost is expected to be recognized is approximately 1.3 years. The weighted average grant date fair value per share of restricted stock granted during 2024, 2023 and 2022 was $ 20.70 , $ 17.33 and $ 20.16 , respectively. The total fair value of restricted stock, which vested during 2024, 2023 and 2022, was $ 6.5 million, $ 3.3 million and $ 2.3 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
During 2024, 2023 and 2022, the Company granted performance awards associated with the Company’s Class A stock to certain senior officers, which are contingent upon achievement of specific revenue growth and EBITDA margin performance goals over a stated period of time ("performance awards"). The maximum number of performance shares that may be earned is 200 % of the target shares originally granted. These awards have three one-year performance periods with the payout for each performance period based on separate financial measure goals that are set in February of each of the three performance periods. Earned shares during each performance period will cliff vest in February subsequent to the third performance period, after approval of the financial results by the Compensation Committee, if not forfeited by the recipient. No dividends are paid on these performance shares. | text | 200 | percentItemType | text: <entity> 200 </entity> <entity type> percentItemType </entity type> <context> During 2024, 2023 and 2022, the Company granted performance awards associated with the Company’s Class A stock to certain senior officers, which are contingent upon achievement of specific revenue growth and EBITDA margin performance goals over a stated period of time ("performance awards"). The maximum number of performance shares that may be earned is 200 % of the target shares originally granted. These awards have three one-year performance periods with the payout for each performance period based on separate financial measure goals that are set in February of each of the three performance periods. Earned shares during each performance period will cliff vest in February subsequent to the third performance period, after approval of the financial results by the Compensation Committee, if not forfeited by the recipient. No dividends are paid on these performance shares. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. | text | 19.96 | perShareItemType | text: <entity> 19.96 </entity> <entity type> perShareItemType </entity type> <context> The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. | text | 16.87 | perShareItemType | text: <entity> 16.87 </entity> <entity type> perShareItemType </entity type> <context> The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. | text | 19.07 | perShareItemType | text: <entity> 19.07 </entity> <entity type> perShareItemType </entity type> <context> The 2024, 2023 and 2022 performance awards have a weighted average grant date fair value of $ 19.96 , $ 16.87 and $ 19.07 , respectively, which was determined by the market price on the date of grant less the present value of the expected dividends not received during the vesting period. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. | text | 170000 | sharesItemType | text: <entity> 170000 </entity> <entity type> sharesItemType </entity type> <context> The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. | text | 211000 | sharesItemType | text: <entity> 211000 </entity> <entity type> sharesItemType </entity type> <context> The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. | text | 165000 | sharesItemType | text: <entity> 165000 </entity> <entity type> sharesItemType </entity type> <context> The total nonvested shares related to 2024, 2023 and 2022 performance awards at year-end 2024 is 170,000 , 211,000 and 165,000 , respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . | text | 115000 | sharesItemType | text: <entity> 115000 </entity> <entity type> sharesItemType </entity type> <context> In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . | text | 22.59 | perShareItemType | text: <entity> 22.59 </entity> <entity type> perShareItemType </entity type> <context> In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . | text | 22000 | sharesItemType | text: <entity> 22000 </entity> <entity type> sharesItemType </entity type> <context> In December 2020, the Company granted 115,000 performance shares to certain senior officers, which were contingent upon the achievement of a specific operating earnings performance goal with a one-year performance period. These performance shares vest over four years and earn dividends, which are not paid until the awards vest, if not forfeited by the recipient. The 2020 performance awards had a weighted average grant date fair value of $ 22.59 per share, which was determined by the market price on the date of grant. On February 15, 2022, the Compensation Committee approved the actual performance achievement of these performance awards. The total nonvested shares related to 2020 performance awards at year-end 2024 is 22,000 . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. | text | 3.4 | monetaryItemType | text: <entity> 3.4 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. | text | 2.6 | monetaryItemType | text: <entity> 2.6 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. | text | 3.4 | monetaryItemType | text: <entity> 3.4 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, unrecognized compensation cost related to all unvested performance shares totaled $ 3.4 million. The weighted average period over which the costs are expected to be recognized is approximately 1.3 years for performance shares. The total fair value of performance shares, which vested during 2024, 2023 and 2022, was $ 2.6 million, $ 3.4 million and $ 0.9 million, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. | text | 7.5 | monetaryItemType | text: <entity> 7.5 </entity> <entity type> monetaryItemType </entity type> <context> On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. </context> | us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration |
On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. | text | 4.5 | monetaryItemType | text: <entity> 4.5 </entity> <entity type> monetaryItemType </entity type> <context> On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. </context> | us-gaap:ProceedsFromSaleOfOtherProductiveAssets |
On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. </context> | us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent |
On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. </context> | us-gaap:GainLossOnDispositionOfAssets1 |
On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> On June 10, 2024, the Company sold Ayers Group, a division of our OCG segment, for a purchase price of $ 7.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 4.5 million in the second quarter of 2024 for assets sold with a net carrying value of $ 1.0 million. In the third quarter of 2024, a post-close net working capital adjustment of $ 0.1 million was recorded in gain on sale of assets in the consolidated statements of earnings. A gain of $ 5.4 million was recorded in gain on sale of assets for the year-ended 2024 in the consolidated statements of earnings. The sale was a part of the Company's ongoing strategy to further optimize its operating model. </context> | us-gaap:GainLossOnDispositionOfAssets1 |
In October 2022, Kelly Properties, LLC, a wholly owned subsidiary of the Company, sold real property located in Troy, Michigan for a purchase price of $ 6.0 million, subject to final closing adjustments. The Company received cash proceeds of $ 5.6 million in the fourth quarter of 2022, net of commissions and transaction expenses. As of the date of the sale, the property | text | 5.6 | monetaryItemType | text: <entity> 5.6 </entity> <entity type> monetaryItemType </entity type> <context> In October 2022, Kelly Properties, LLC, a wholly owned subsidiary of the Company, sold real property located in Troy, Michigan for a purchase price of $ 6.0 million, subject to final closing adjustments. The Company received cash proceeds of $ 5.6 million in the fourth quarter of 2022, net of commissions and transaction expenses. As of the date of the sale, the property </context> | us-gaap:ProceedsFromSaleOfPropertyHeldForSale |
had a carrying value of $ 4.7 million, resulting in a $ 0.9 million gain on the sale, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 4.7 | monetaryItemType | text: <entity> 4.7 </entity> <entity type> monetaryItemType </entity type> <context> had a carrying value of $ 4.7 million, resulting in a $ 0.9 million gain on the sale, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:RealEstateHeldforsale |
had a carrying value of $ 4.7 million, resulting in a $ 0.9 million gain on the sale, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> had a carrying value of $ 4.7 million, resulting in a $ 0.9 million gain on the sale, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:GainLossOnSaleOfProperties |
In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:ProceedsFromSaleOfLandHeldforinvestment |
In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 0.8 | monetaryItemType | text: <entity> 0.8 </entity> <entity type> monetaryItemType </entity type> <context> In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:ProceedsFromSaleOfLandHeldforinvestment |
In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 4.4 | monetaryItemType | text: <entity> 4.4 </entity> <entity type> monetaryItemType </entity type> <context> In June 2022, the Company sold an under-utilized real property for a purchase price of $ 4.5 million, subject to final closing adjustments. The Company received cash proceeds of $ 3.6 million in the second quarter of 2022 and previously received cash proceeds of $ 0.8 million as a deposit in 2021 when the contract was first executed. As of the date of the sale, the land had insignificant carrying value; as such, the resulting gain on the sale was $ 4.4 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:GainLossOnSaleOfProperties |
In January 2022, the Company sold a property for a purchase price of $ 0.9 million, subject to final closing adjustments. The Company received cash proceeds of $ 0.9 million in the first quarter of 2022. As of the date of the sale, the property had an immaterial carrying value; as such, the resulting gain on the sale of the property was $ 0.9 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> In January 2022, the Company sold a property for a purchase price of $ 0.9 million, subject to final closing adjustments. The Company received cash proceeds of $ 0.9 million in the first quarter of 2022. As of the date of the sale, the property had an immaterial carrying value; as such, the resulting gain on the sale of the property was $ 0.9 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:ProceedsFromSaleOfPropertyHeldForSale |
In January 2022, the Company sold a property for a purchase price of $ 0.9 million, subject to final closing adjustments. The Company received cash proceeds of $ 0.9 million in the first quarter of 2022. As of the date of the sale, the property had an immaterial carrying value; as such, the resulting gain on the sale of the property was $ 0.9 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> In January 2022, the Company sold a property for a purchase price of $ 0.9 million, subject to final closing adjustments. The Company received cash proceeds of $ 0.9 million in the first quarter of 2022. As of the date of the sale, the property had an immaterial carrying value; as such, the resulting gain on the sale of the property was $ 0.9 million, which was recorded in gain on sale of assets in the consolidated statements of earnings. </context> | us-gaap:GainLossOnSaleOfProperties |
As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. | text | 330.1 | monetaryItemType | text: <entity> 330.1 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. | text | 324.8 | monetaryItemType | text: <entity> 324.8 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. | text | 321.1 | monetaryItemType | text: <entity> 321.1 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> As of year-end 2024, the net deferred tax asset balance totaled $ 330.1 million which is fully recorded in deferred taxes in the consolidated balance sheet. As of year-end 2023, the net deferred tax asset balance totaled $ 324.8 million with $ 321.1 million in deferred taxes, $ 4.1 million in assets held for sale (see Acquisitions and Dispositions footnote), and $ 0.4 million in other long-term liabilities in the consolidated balance sheet. </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in | text | 197.3 | monetaryItemType | text: <entity> 197.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in </context> | us-gaap:TaxCreditCarryforwardAmount |
The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in | text | 33.2 | monetaryItemType | text: <entity> 33.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in </context> | us-gaap:TaxCreditCarryforwardAmount |
The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in | text | 30.5 | monetaryItemType | text: <entity> 30.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in </context> | us-gaap:OperatingLossCarryforwards |
The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in | text | 19.6 | monetaryItemType | text: <entity> 19.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company has U.S. general business credit carryforwards of $ 197.3 million which will expire from 2034 to 2044, foreign tax credit carryforwards of $ 33.2 million which will expire from 2026 to 2034 and minimal state and foreign credit carryforwards which are either indefinite or will expire from 2025 to 2043. The net tax effect of federal, state and foreign loss carryforwards at year-end 2024 totaled $ 30.5 million, comprised of $ 19.6 million of capital loss carryforwards that expire in </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration |
2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. | text | 10.9 | monetaryItemType | text: <entity> 10.9 </entity> <entity type> monetaryItemType </entity type> <context> 2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. </context> | us-gaap:OperatingLossCarryforwards |
2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. | text | 9.1 | monetaryItemType | text: <entity> 9.1 </entity> <entity type> monetaryItemType </entity type> <context> 2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration |
2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> 2029, and $ 10.9 million of net operating loss carryforwards of which $ 9.1 million have no expiration and $ 1.8 million expire between 2025 and 2044. </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 24.4 | monetaryItemType | text: <entity> 24.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 19.6 | monetaryItemType | text: <entity> 19.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:DeferredTaxAssetsCapitalLossCarryforwards |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 21.4 | monetaryItemType | text: <entity> 21.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 19.2 | monetaryItemType | text: <entity> 19.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:DeferredTaxAssetsCapitalLossCarryforwards |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 15.0 | monetaryItemType | text: <entity> 15.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets | text | 14.5 | monetaryItemType | text: <entity> 14.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company has established a valuation allowance for certain loss carryforwards, future deductible items, outside basis differences, and for a portion of its U.S. foreign tax credit carryforwards. The decrease in valuation allowance during 2024 was primarily due to the Company’s sale of its EMEA staffing operations which included companies with $ 24.4 million of valuation allowances. The outside basis difference included in the 2023 deferred balance was for held for sale assets at the end of 2023 which were sold during the first quarter of 2024 when the Company completed the sale of its EMEA staffing operations. This transaction generated a capital loss, $ 19.6 million of which is carried forward. A valuation allowance of $ 21.4 million was recorded against the outside basis difference at year-end 2023, and $ 19.2 million against the capital loss carryforward at year-end 2024. The foreign tax credit valuation allowance is $ 15.0 million at year-end 2024 and $ 14.5 million at year-end 2023 and will continue to be monitored. The valuation allowance is determined in accordance with the provisions of ASC 740, "Income Taxes," which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. The Company’s uncertainty in the ability to create future capital gains, and its recent lack of adequate U.S. foreign source income to fully utilize foreign tax credit carryforwards, represented sufficient negative evidence to require a valuation allowance under ASC 740. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support realization of the deferred tax assets </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 18.5 | monetaryItemType | text: <entity> 18.5 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:IncomeTaxExpenseBenefit |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 6.2 | monetaryItemType | text: <entity> 6.2 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:CashSurrenderValueOfLifeInsurance |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 15.0 | monetaryItemType | text: <entity> 15.0 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:IncomeTaxExpenseBenefit |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 6.5 | monetaryItemType | text: <entity> 6.5 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:CashSurrenderValueOfLifeInsurance |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 16.9 | monetaryItemType | text: <entity> 16.9 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:IncomeTaxExpenseBenefit |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 7.1 | monetaryItemType | text: <entity> 7.1 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:IncomeTaxExpenseBenefit |
lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. | text | 7.8 | monetaryItemType | text: <entity> 7.8 </entity> <entity type> monetaryItemType </entity type> <context> lower pretax earnings, which included an $ 18.5 million benefit from the impairment of tax-deductible goodwill and a $ 6.2 million benefit from tax-exempt life insurance cash surrender value gains. 2023 benefited from recording a $ 15.0 million federal and state benefit on the outside basis difference in held for sale assets, and a $ 6.5 million benefit from tax-exempt life insurance cash surrender value gains. 2022 benefited from lower pretax earnings, which included benefits of $ 16.9 million from changes in the fair value of the Company's investment in Persol Holdings and $ 7.1 million from the impairment of tax-deductible goodwill. These benefits were offset by a $ 7.8 million charge from tax exempt life insurance cash surrender value losses. </context> | us-gaap:CashSurrenderValueOfLifeInsurance |
Provision has not been made for additional income taxes on an estimated $ 65.6 million of foreign subsidiary undistributed earnings which are indefinitely reinvested. If these earnings were to be repatriated, the Company could be subject to foreign withholding tax, federal and state income tax, net of federal benefit, and income taxes on foreign exchange gains or losses, of $ 4.7 million. | text | 65.6 | monetaryItemType | text: <entity> 65.6 </entity> <entity type> monetaryItemType </entity type> <context> Provision has not been made for additional income taxes on an estimated $ 65.6 million of foreign subsidiary undistributed earnings which are indefinitely reinvested. If these earnings were to be repatriated, the Company could be subject to foreign withholding tax, federal and state income tax, net of federal benefit, and income taxes on foreign exchange gains or losses, of $ 4.7 million. </context> | us-gaap:UndistributedEarningsOfForeignSubsidiaries |
Provision has not been made for additional income taxes on an estimated $ 65.6 million of foreign subsidiary undistributed earnings which are indefinitely reinvested. If these earnings were to be repatriated, the Company could be subject to foreign withholding tax, federal and state income tax, net of federal benefit, and income taxes on foreign exchange gains or losses, of $ 4.7 million. | text | 4.7 | monetaryItemType | text: <entity> 4.7 </entity> <entity type> monetaryItemType </entity type> <context> Provision has not been made for additional income taxes on an estimated $ 65.6 million of foreign subsidiary undistributed earnings which are indefinitely reinvested. If these earnings were to be repatriated, the Company could be subject to foreign withholding tax, federal and state income tax, net of federal benefit, and income taxes on foreign exchange gains or losses, of $ 4.7 million. </context> | us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings |
If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. </context> | us-gaap:UnrecognizedTaxBenefits |
If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. | text | 0.6 | monetaryItemType | text: <entity> 0.6 </entity> <entity type> monetaryItemType </entity type> <context> If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. </context> | us-gaap:UnrecognizedTaxBenefits |
If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> If the $ 0.5 million in 2024, $ 0.6 million in 2023 and $ 0.5 million in 2022 of unrecognized tax benefits were recognized, they would have a favorable effect of $ 0.4 million in 2024, $ 0.5 million in 2023 and $ 0.4 million in 2022 on income tax expense. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
The Company recognizes both interest and penalties as part of the income tax provision. The Company recognized an insignificant benefit in 2024 and $ 0.1 million of expense in 2023, for interest and penalties. The benefit recognized in 2022 was not significant. Accrued interest and penalties were $ 0.2 million at year-end 2024 and $ 0.2 million at year-end 2023. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognizes both interest and penalties as part of the income tax provision. The Company recognized an insignificant benefit in 2024 and $ 0.1 million of expense in 2023, for interest and penalties. The benefit recognized in 2022 was not significant. Accrued interest and penalties were $ 0.2 million at year-end 2024 and $ 0.2 million at year-end 2023. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense |
The Company recognizes both interest and penalties as part of the income tax provision. The Company recognized an insignificant benefit in 2024 and $ 0.1 million of expense in 2023, for interest and penalties. The benefit recognized in 2022 was not significant. Accrued interest and penalties were $ 0.2 million at year-end 2024 and $ 0.2 million at year-end 2023. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company recognizes both interest and penalties as part of the income tax provision. The Company recognized an insignificant benefit in 2024 and $ 0.1 million of expense in 2023, for interest and penalties. The benefit recognized in 2022 was not significant. Accrued interest and penalties were $ 0.2 million at year-end 2024 and $ 0.2 million at year-end 2023. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued |
The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. </context> | us-gaap:InterestPaidNet |
The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. | text | 2.8 | monetaryItemType | text: <entity> 2.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. </context> | us-gaap:InterestPaidNet |
The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. </context> | us-gaap:InterestPaidNet |
The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. | text | 10.9 | monetaryItemType | text: <entity> 10.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. </context> | us-gaap:IncomeTaxesPaidNet |
The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. | text | 8.9 | monetaryItemType | text: <entity> 8.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company paid interest of $ 10.0 million in 2024, $ 2.8 million in 2023 and $ 1.3 million in 2022. The Company paid income taxes of $ 10.9 million in 2024, $ 8.9 million in 2023 and $ 61.2 million in 2022. </context> | us-gaap:IncomeTaxesPaidNet |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.